Header Logo

Connection

Allison Naleway to Adolescent

Back to Details
This is a "connection" page, showing publications Allison Naleway has written about Adolescent.
Allison Naleway
Connection Strength
3.020
Adolescent
  1. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years. JAMA. 2024 02 06; 331(5):408-416.
    View in: PubMed
    Score: 0.130
  2. Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among Persons Aged =12 Years, by COVID-19 Vaccination Status - Oregon and Washington, July 4-September 25, 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 19; 70(46):1608-1612.
    View in: PubMed
    Score: 0.111
  3. Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination. Vaccine. 2021 06 16; 39(27):3614-3620.
    View in: PubMed
    Score: 0.107
  4. Temporal Trends in the Incidence of Anogenital Warts: Impact of Human Papillomavirus Vaccination. Sex Transm Dis. 2020 03; 47(3):179-186.
    View in: PubMed
    Score: 0.099
  5. Uptake and safety of hepatitis A vaccination during pregnancy: A Vaccine Safety Datalink study. Vaccine. 2019 10 16; 37(44):6648-6655.
    View in: PubMed
    Score: 0.096
  6. Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study. Vaccine. 2018 10 01; 36(41):6111-6116.
    View in: PubMed
    Score: 0.089
  7. Feasibility of a pilot intervention to reduce pain and syncope during adolescent vaccination. Vaccine. 2018 06 22; 36(27):3937-3942.
    View in: PubMed
    Score: 0.087
  8. Implementing a Multipartner HPV Vaccination Assessment and Feedback Intervention in an Integrated Health System. J Public Health Manag Pract. 2017 Nov/Dec; 23(6):589-592.
    View in: PubMed
    Score: 0.084
  9. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011. Vaccine. 2016 Jan 02; 34(1):167-71.
    View in: PubMed
    Score: 0.073
  10. Pregnancy after treatment for cervical cancer precursor lesions in a retrospective matched cohort. PLoS One. 2015; 10(2):e0117525.
    View in: PubMed
    Score: 0.069
  11. Evaluation of a surveillance case definition for anogenital warts, Kaiser Permanente northwest. Sex Transm Dis. 2014 Aug; 41(8):496-500.
    View in: PubMed
    Score: 0.067
  12. Monovalent H1N1 influenza vaccine safety in pregnant women, risks for acute adverse events. Vaccine. 2014 Sep 03; 32(39):4985-92.
    View in: PubMed
    Score: 0.067
  13. Barriers and facilitators to influenza vaccination and vaccine coverage in a cohort of health care personnel. Am J Infect Control. 2014 Apr; 42(4):371-5.
    View in: PubMed
    Score: 0.065
  14. Vaccinations given during pregnancy, 2002-2009: a descriptive study. Am J Prev Med. 2014 Feb; 46(2):150-7.
    View in: PubMed
    Score: 0.065
  15. Uptake, coverage, and completion of quadrivalent human papillomavirus vaccine in the vaccine safety Datalink, July 2006-June 2011. J Adolesc Health. 2013 Nov; 53(5):637-41.
    View in: PubMed
    Score: 0.064
  16. Identifying pregnancy episodes, outcomes, and mother-infant pairs in the Vaccine Safety Datalink. Vaccine. 2013 Jun 12; 31(27):2898-903.
    View in: PubMed
    Score: 0.061
  17. Reported adverse events in young women following quadrivalent human papillomavirus vaccination. J Womens Health (Larchmt). 2012 Apr; 21(4):425-32.
    View in: PubMed
    Score: 0.056
  18. Frequency of medically attended events following rapid revaccination with trivalent inactivated influenza vaccine. Vaccine. 2010 Nov 16; 28(49):7713-5.
    View in: PubMed
    Score: 0.051
  19. Risk of immune hemolytic anemia in children following immunization. Vaccine. 2009 Dec 09; 27(52):7394-7.
    View in: PubMed
    Score: 0.048
  20. Epidemiology of systemic lupus erythematosus in rural Wisconsin. Lupus. 2005; 14(10):862-6.
    View in: PubMed
    Score: 0.034
  21. Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
    View in: PubMed
    Score: 0.033
  22. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged =18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 28; 73(12):271-276.
    View in: PubMed
    Score: 0.033
  23. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged =18 Years - VISION and IVY Networks, September 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024 Feb 29; 73(8):180-188.
    View in: PubMed
    Score: 0.033
  24. Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. Vaccine. 2023 09 07; 41(39):5678-5682.
    View in: PubMed
    Score: 0.031
  25. Eczematous skin disease and recall of past diagnoses: implications for smallpox vaccination. Ann Intern Med. 2003 Jul 01; 139(1):1-7.
    View in: PubMed
    Score: 0.031
  26. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep. 2023 May 26; 72(21):579-588.
    View in: PubMed
    Score: 0.031
  27. Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents. Pediatrics. 2023 05 01; 151(5).
    View in: PubMed
    Score: 0.031
  28. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 17; 71(53):1637-1646.
    View in: PubMed
    Score: 0.030
  29. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 30; 71(5152):1616-1624.
    View in: PubMed
    Score: 0.030
  30. Extended surveillance to assess safety of 9-valent human papillomavirus vaccine. Hum Vaccin Immunother. 2022 12 30; 18(7):2159215.
    View in: PubMed
    Score: 0.030
  31. Receipt of COVID-19 Booster Dose Among Fully Vaccinated Pregnant Individuals Aged 18 to 49 Years by Key Demographics. JAMA. 2022 06 21; 327(23):2351-2354.
    View in: PubMed
    Score: 0.029
  32. Lyme disease incidence in Wisconsin: a comparison of state-reported rates and rates from a population-based cohort. Am J Epidemiol. 2002 Jun 15; 155(12):1120-7.
    View in: PubMed
    Score: 0.029
  33. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 01; 71(13):495-502.
    View in: PubMed
    Score: 0.028
  34. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 18; 71(11):422-428.
    View in: PubMed
    Score: 0.028
  35. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
    View in: PubMed
    Score: 0.028
  36. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
    View in: PubMed
    Score: 0.028
  37. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.028
  38. Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance - Nine States, June-August 2021. MMWR Morb Mortal Wkly Rep. 2021 09 17; 70(37):1291-1293.
    View in: PubMed
    Score: 0.027
  39. COVID-19 Vaccination Coverage Among Insured Persons Aged =16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 16; 70(28):985-990.
    View in: PubMed
    Score: 0.027
  40. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021 07 22; 385(4):320-329.
    View in: PubMed
    Score: 0.027
  41. COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 8, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jun 18; 70(24):895-899.
    View in: PubMed
    Score: 0.027
  42. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 02; 70(13):495-500.
    View in: PubMed
    Score: 0.027
  43. Evaluating the Association of Stillbirths After Maternal Vaccination in the Vaccine Safety Datalink. Obstet Gynecol. 2020 12; 136(6):1086-1094.
    View in: PubMed
    Score: 0.026
  44. SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics - Eight U.S. Health Care Centers, March 1-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 23; 69(38):1355-1359.
    View in: PubMed
    Score: 0.026
  45. Epidemiology and Clinical Outcomes of Hospitalizations for Acute Respiratory or Febrile Illness and Laboratory-Confirmed Influenza Among Pregnant Women During Six Influenza Seasons, 2010-2016. J Infect Dis. 2020 04 27; 221(10):1703-1712.
    View in: PubMed
    Score: 0.025
  46. Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics. 2019 12; 144(6).
    View in: PubMed
    Score: 0.024
  47. Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15. Vaccine. 2019 10 16; 37(44):6673-6681.
    View in: PubMed
    Score: 0.024
  48. Incidence of Herpes Zoster Among Children: 2003-2014. Pediatrics. 2019 07; 144(1).
    View in: PubMed
    Score: 0.023
  49. A model for rapid, active surveillance for medically-attended acute gastroenteritis within an integrated health care delivery system. PLoS One. 2018; 13(8):e0201805.
    View in: PubMed
    Score: 0.022
  50. Estimated rates of influenza-associated outpatient visits during 2001-2010 in 6 US integrated healthcare delivery organizations. Influenza Other Respir Viruses. 2018 01; 12(1):122-131.
    View in: PubMed
    Score: 0.021
  51. Myocarditis and pericarditis are rare following live viral vaccinations in adults. Vaccine. 2018 03 14; 36(12):1524-1527.
    View in: PubMed
    Score: 0.021
  52. Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. BMC Pulm Med. 2017 Dec 16; 17(1):208.
    View in: PubMed
    Score: 0.021
  53. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy. Obstet Gynecol. 2017 09; 130(3):599-608.
    View in: PubMed
    Score: 0.021
  54. Maternal Tdap vaccination and risk of infant morbidity. Vaccine. 2017 06 22; 35(29):3655-3660.
    View in: PubMed
    Score: 0.020
  55. Live attenuated influenza vaccine use and safety in children and adults with asthma. Ann Allergy Asthma Immunol. 2017 04; 118(4):439-444.
    View in: PubMed
    Score: 0.020
  56. Predictors of Breastfeeding Initiation and Maintenance in an Integrated Healthcare Setting. J Hum Lact. 2017 May; 33(2):256-266.
    View in: PubMed
    Score: 0.020
  57. Pregnancy Outcomes after Treatment for Cervical Cancer Precursor Lesions: An Observational Study. PLoS One. 2017; 12(1):e0165276.
    View in: PubMed
    Score: 0.020
  58. Identifying birth defects in automated data sources in the Vaccine Safety Datalink. Pharmacoepidemiol Drug Saf. 2017 Apr; 26(4):412-420.
    View in: PubMed
    Score: 0.020
  59. Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis. Clin Infect Dis. 2016 Dec 01; 63(11):1456-1462.
    View in: PubMed
    Score: 0.019
  60. Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013. Vaccine. 2016 Feb 10; 34(7):968-73.
    View in: PubMed
    Score: 0.018
  61. Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. Obstet Gynecol. 2015 Nov; 126(5):1069-74.
    View in: PubMed
    Score: 0.018
  62. Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. JAMA. 2015 Oct 20; 314(15):1581-7.
    View in: PubMed
    Score: 0.018
  63. Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States population. Vaccine. 2015 Aug 26; 33(36):4446-50.
    View in: PubMed
    Score: 0.018
  64. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA. 2014 Nov 12; 312(18):1897-904.
    View in: PubMed
    Score: 0.017
  65. Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink sites. Prev Med. 2014 Oct; 67:316-9.
    View in: PubMed
    Score: 0.017
  66. Comparison of laboratory-confirmed influenza and noninfluenza acute respiratory illness in healthcare personnel during the 2010-2011 influenza season. Infect Control Hosp Epidemiol. 2014 May; 35(5):538-46.
    View in: PubMed
    Score: 0.016
  67. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season. Pharmacoepidemiol Drug Saf. 2014 May; 23(5):548-53.
    View in: PubMed
    Score: 0.016
  68. Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine. J Infect Dis. 2014 Jun 01; 209(11):1705-14.
    View in: PubMed
    Score: 0.016
  69. Safety of the yellow Fever vaccine: a retrospective study. J Travel Med. 2013 Nov-Dec; 20(6):368-73.
    View in: PubMed
    Score: 0.016
  70. Inactivated influenza vaccine during pregnancy and risks for adverse obstetric events. Obstet Gynecol. 2013 Sep; 122(3):659-67.
    View in: PubMed
    Score: 0.016
  71. Mortality rates and cause-of-death patterns in a vaccinated population. Am J Prev Med. 2013 Jul; 45(1):91-97.
    View in: PubMed
    Score: 0.016
  72. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine. 2013 May 24; 31(22):2578-83.
    View in: PubMed
    Score: 0.015
  73. Cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ: comparison of ICD-9 codes and pathology results--Kaiser Permanente, United States, 2000-2005. Cancer Epidemiol Biomarkers Prev. 2013 Jun; 22(6):1129-32.
    View in: PubMed
    Score: 0.015
  74. Predictors of seasonal influenza vaccination during pregnancy. Obstet Gynecol. 2013 Apr; 121(4):741-9.
    View in: PubMed
    Score: 0.015
  75. Maternal safety of trivalent inactivated influenza vaccine in pregnant women. Obstet Gynecol. 2013 Mar; 121(3):519-25.
    View in: PubMed
    Score: 0.015
  76. Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact. Cancer Causes Control. 2013 Feb; 24(2):403-7.
    View in: PubMed
    Score: 0.015
  77. Trivalent inactivated influenza vaccine and spontaneous abortion. Obstet Gynecol. 2013 Jan; 121(1):159-65.
    View in: PubMed
    Score: 0.015
  78. Secular trends in diagnostic code density in electronic healthcare data from health care systems in the Vaccine Safety Datalink project. Vaccine. 2013 Feb 04; 31(7):1080-5.
    View in: PubMed
    Score: 0.015
  79. Factors predicting completion of the human papillomavirus vaccine series. J Adolesc Health. 2013 Apr; 52(4):427-32.
    View in: PubMed
    Score: 0.015
  80. Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000-2010. Influenza Other Respir Viruses. 2012 Nov; 6(6):e143-51.
    View in: PubMed
    Score: 0.014
  81. The expected emotional benefits of influenza vaccination strongly affect pre-season intentions and subsequent vaccination among healthcare personnel. Vaccine. 2012 May 21; 30(24):3557-65.
    View in: PubMed
    Score: 0.014
  82. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011 Oct 26; 29(46):8279-84.
    View in: PubMed
    Score: 0.014
  83. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am J Prev Med. 2011 Aug; 41(2):121-8.
    View in: PubMed
    Score: 0.014
  84. Monitoring vaccine safety using the Vaccine Safety Datalink: utilizing immunization registries for pandemic influenza. Vaccine. 2011 Jul 12; 29(31):4891-6.
    View in: PubMed
    Score: 0.013
  85. Completion and timing of the three-dose human papillomavirus vaccine series among adolescents attending school-based health centers in Oregon. Prev Med. 2011 Jun; 52(6):456-8.
    View in: PubMed
    Score: 0.013
  86. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. Pediatrics. 2011 May; 127 Suppl 1:S54-64.
    View in: PubMed
    Score: 0.013
  87. Frequency of medically attended adverse events following tetanus and diphtheria toxoid vaccine in adolescents and young adults: a Vaccine Safety Datalink study. BMC Infect Dis. 2009 Oct 05; 9:165.
    View in: PubMed
    Score: 0.012
  88. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009 Oct; 99 Suppl 2:S389-97.
    View in: PubMed
    Score: 0.012
  89. Risk of medically attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: a Vaccine Safety Datalink study. Vaccine. 2009 Aug 06; 27(36):4912-6.
    View in: PubMed
    Score: 0.012
  90. Varicella vaccination and ischemic stroke in children: is there an association? Pediatrics. 2009 Feb; 123(2):e228-34.
    View in: PubMed
    Score: 0.011
  91. Asthma and farm exposures in a cohort of rural Iowa children. Environ Health Perspect. 2005 Mar; 113(3):350-6.
    View in: PubMed
    Score: 0.009

© 2024 Kaiser Permanente